The Filing Desk

Scholar Rock

SRRK · Nasdaq · Health Care · Financials, fiscal 2017 to 2025

SRRK · Last close · November 13, 2026
$43.20
Value Scholar Rock yourself

Scholar Rock reported revenue of $0 million in fiscal 2025. Free cash flow was −$301 million. The diluted share count rose 14.9%.

SCHOLAR ROCK HOLDING CORPORATION Latest fiscal year ended December 31, 2025 10-K filed March 3, 2026 · 0001104659-26-022551 Updated
Revenue
$0M
 
Net margin
—
 
Net income
−$378M
 
Free cash flow
−$301M
 
Return on equity
−123.1%
40.1 pts
Market cap
$5.7B
Nov 13 close
P/E
—
Loss: no P/E

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Scholar Rock does

Scholar Rock is a biotechnology company developing antibody drugs for spinal muscular atrophy (SMA) and other rare muscle-wasting diseases. It has no approved product yet and no product sales. It says 2026 could be the year it becomes a commercial-stage company, if regulators approve its lead drug.

Its technology targets growth factors in the TGF-beta family, a group of signaling proteins. Its drugs bind the inactive forms of these proteins in muscle. The lead candidate, apitegromab, blocks myostatin, a protein that limits muscle growth, in the hope of building muscle mass and strength. The company reported positive results from a late-stage trial in children and adults with SMA in October 2024 and says it expects regulatory decisions in the United States and Europe in 2026.

The company also plans a mid-stage study of apitegromab in facioscapulohumeral muscular dystrophy (FSHD) and is developing a version given as an injection under the skin, rather than through a vein. A second candidate, SRK-439, is also an antibody that targets myostatin. Because it has no sales, the company relies on money it raises to pay for its work.

Its biggest risks, as it describes them

  • Its lead drug may not be approved, or may be approved only with limits on how it can be used.
  • Even if approved, apitegromab may not win acceptance from doctors, patients and insurers.
  • Its clinical development depends on the continued availability of other companies' approved drug therapies.
  • Results from early trials may not predict later ones, and early data it announces may change.
  • Delays in enrolling patients could slow its trials and raise its costs.
From Scholar Rock's annual report on Form 10-K, filed March 3, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Scholar Rock lost money in fiscal 2025: a net loss of $378 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments253315280437368
Debt incl. finance leases54515250100
Net debt (negative means net cash)−199−264−228−387−268
Net debt to EBITDA—————
Debt to equity0.3x0.2x0.2x0.1x0.4x
Interest coverage−61.9x−28.6x−26.4x−36.9x−55.8x
Current ratio4.1x9.0x8.8x9.6x7.0x
Quick ratio4.1x9.0x8.8x9.6x7.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Scholar Rock's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Scholar Rock shares on the open market, and 13 insiders sold $19.4 million, $8.8 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jul 1, 2026Katie PengDirectorSold plan5,446$53.87$293,399Form 4
Jul 1, 2026Jeffrey S. FlierDirectorSold plan3,053$53.88$164,491Form 4
Jul 1, 2026Joshua ReedDirectorSold plan3,053$53.74$164,075Form 4
Jul 1, 2026Kristina BurowDirectorSold plan3,053$53.74$164,054Form 4
Jul 1, 2026Michael GilmanDirectorSold plan2,544$53.87$137,057Form 4
Apr 16, 2026David HallalChief Executive Officer, DirectorSold30,615$49.57$1.5 millionForm 4
Apr 16, 2026Akshay VaishnawPresident of R&D, DirectorSold12,246$49.57$607,034Form 4
Apr 16, 2026Vikas SinhaChief Financial OfficerSold10,410$49.57$516,024Form 4
Apr 16, 2026Keith WoodsChief Operating OfficerSold10,220$49.57$506,605Form 4
Feb 23, 2026Mo QatananiChief Scientific OfficerSold plan8,484$47.07$399,335Form 4
Feb 17, 2026Junlin HoGeneral CounselSold9,580$46.53$445,757Form 4
Feb 17, 2026Caryn ParlavecchioCHROSold9,035$46.53$420,399Form 4
The latest 12 of 26 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40———
Altman Z''−2.65−0.68−9.91
Accruals ratio−6.2%−11.5%−17.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassFail
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assets———
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Scholar Rock side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Scholar RockFY25——————
AbbVieFY258.6%24.6%29.1%15.7%2.7x7Compare
AbsciFY25−38.2%−4,297.0%−3,358.3%−162.8%—3Compare
Arbutus BiopharmaFY25128.2%−271.0%−281.4%——3Compare
ADMA BiologicsFY2519.6%37.5%5.5%39.5%−0.1x5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

9 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—020151933——0
Revenue growth———−24.8%22.2%76.4%———
Gross profit—————————
Research and development20365474108124122184208
Operating income−25−51−54−87−130−134−171−252−385
Net income−25−49−51−86−132−134−166−246−378
Diluted EPS (US$)−15.30−3.15−1.85−2.81−3.59−2.26−1.99−2.47−3.29
Diluted shares (millions)2162831376083100115
Cash flow
Cash from operations−2225−63−60−127−133−145−201−300
Capital expenditure023451001
Free cash flow−2223−66−64−132−134−145−201−301
Dividends paid000000000
Share buybacks000000000
Acquisitions000000000
Stock-based compensation258112328273776
Balance sheet at fiscal year end
Cash and short-term investments58176157341253315280437368
Debt incl. finance leases10—2654515250100
Total assets62181196388304358311475404
Total liabilities675841281329886106159
Shareholders' equity−54107113261172260225369246
Margins and ratios
Gross margin—————————
Operating margin——−266.2%−564.0%−690.5%−404.8%———
Net margin——−248.9%−561.5%−700.5%−405.2%———
Free cash flow margin——−323.2%−417.8%−701.7%−403.0%———
Rule of 40 (growth + FCF margin)———−442.7%−679.6%−326.6%———
Return on capital—————————
Return on equity—−185.8%−46.5%−46.3%−60.9%−62.2%−68.3%−83.0%−123.1%
Return on assets—−40.6%−27.0%−29.6%−38.0%−40.6%−49.5%−62.7%−86.0%
Net debt to EBITDA—————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Scholar Rock's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Scholar Rock.